You can also read the IBTA e-News May 2020 edition in full online here.
Some of the highlights from this month's round-up:
- China National Medical Products Administration (NMPA) has approved the Optune for the treatment of newly diagnosed glioblastoma, as well as a monotherapy for recurrent glioblastoma, marking the first treatment for glioblastoma approved in China in over 15 years
- Results of a phase 3 trial of the checkpoint inhibitor nivolumab (Opdivo) in patients with recurrent glioblastoma showed no survival advantage when compared with bevacizumab (Avastin) therapy,
- Trifluoperazine, a drug used to treat schizophrenia, appears to make glioblastoma tumours more sensitive to radiotherapy, according to an animal-based study.
- A research project to develop an Artificial Intelligence (AI) system for diagnosing brain tumours has been launched and is being led by Intel Labs and Penn Medicine, USA. The project is based on a technique that will allow the 29 institutions -- from the US, Canada, the UK, Germany, the Netherlands, Switzerland and India -- to create a larger data set than any one institution would be able to on its own.
- The angina medication perhexiline may be able to serve as a therapy against glioblastoma, according to preclinical research published in Molecular Cellular Therapeutics.
- Research published in EBiomedicine has found that microRNA, a special type of molecule that controls how genes within a cell operate, is implicated in the way glioblastoma cells develop resistance to radiation therapy.
- Diverse Biotech – a biopharmaceutical company specialising in novel therapeutics utilising cannabidiol (CBD) – has announced that the US Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for the treatment of newly diagnosed glioblastoma.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.